Stackline and Redslim Partner to Deliver Unparalleled Retail Intelligence and Data Integration for Global Brands
19.3.2025 14:00:00 CET | Business Wire | Press release
Stackline, the leader in retail intelligence and data-driven commerce solutions, has announced a strategic partnership with Redslim, a leading data management company specializing in optimizing syndicated market data. This collaboration provides global CPG and CHC brands with a high-fidelity, 360-degree view of category performance—equipping them to make smarter, faster decisions in an increasingly competitive marketplace.
Stackline’s industry-leading solutions provide brands and manufacturers with deep, data-driven insights into category performance. By tracking sales volume, traffic, and conversion rates across the world’s top retail ecosystems, including Amazon, Stackline enables brands to decode the omnichannel shopper journey with precision. Its digital shelf solution delivers advanced analytics to optimize product listings, enhance digital shelf performance, and drive sustained ecommerce growth.
Redslim specializes in transforming fragmented market measurement data into harmonized, ready-to-use datasets. By integrating siloed data sources into centralized analytics systems, Redslim enables businesses to unlock actionable insights on market share, marketing effectiveness, and innovation strategies. This holistic approach ensures brands can leverage their data as a strategic asset, enabling smarter decisions and sustained competitive advantage.
This partnership between Stackline and Redslim fundamentally reshapes how brands harness data, seamlessly integrating Stackline’s intelligence into centralized analytics ecosystems. By unifying online and offline data, brands gain a comprehensive, end-to-end solution for optimizing performance and driving growth. With coverage across North America, Europe, and Asia—where a single marketplace can account for up to 20% of total market share—this collaboration delivers unparalleled visibility into online and omnichannel dynamics.
“Our partnership with Redslim strengthens our ability to deliver unmatched data access and actionable insights,” said Mitch Keidan, Vice President of Strategic Partnerships at Stackline. “By embedding Stackline’s intelligence into Redslim’s systems, we’re unlocking new ways for brands to maximize their data’s potential and fuel smarter, faster decisions.”
Marta Battiston, Chief Strategy Officer at Redslim, added, “By integrating Redslim’s harmonized syndicated market data with Stackline’s omnichannel and retail intelligence, we’re bridging critical data gaps and empowering brands with a truly comprehensive solution for strategic decision-making.”
As digital commerce continues to evolve, the ability to synthesize and interpret ecommerce and omnichannel data is more crucial than ever. Together, Stackline and Redslim are delivering an all-encompassing solution that enables brands to access harmonized market data, gain deeper ecommerce insights, and achieve a holistic view of market performance and competitive intelligence.
About Redslim
Redslim streamlines data management for teams faced with the request to leverage fragmented datasets for critical decision-making. Specialized in data engineering, harmonization, and BI, their teams manage data from over 50 agencies and cover more than 55 countries. Their technology-enabled services optimize data consumption for more than 30 global organizations. Active for more than 10 years, Redslim has constantly innovated their solutions to always meet the evolving needs of their clients and data partners. Learn more at www.redslim.net and follow Redslim on LinkedIn.
About Stackline
On a mission to fuel the future of commerce by bringing brands and customers closer together, Stackline is the leading AI-enabled retail intelligence and activation platform for the world's most innovative brands. Business leaders, product innovators, performance marketers, and financial firms trust Stackline as the single source of commerce truth. Fueled by proprietary neural networks and deep learning systems, Stackline's market insights, revenue metrics, behavioral data, and autonomous functionality create the actions that determine success or failure. Founded in 2014 in Seattle, Stackline employs over 250 connected commerce professionals creating value for 7,000 global brands.
Learn more by visiting https://www.stackline.com/partners or contact media@stackline.com. Follow Stackline on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250319045474/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom